Accepted at 5:24 p.m. Oct, 31, 2023 by Alex
Author: evanskj
Related Note: 1474340647578
Rationale for change

Protein C & S are vitamin K dependent and have shorter half-lives

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::^Systems::Respiratory::Pathology #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::02_Warfarin #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::10_Anticoagulation #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Other::^EXPN::BGedit #AK_Step1_v12::#AMBOSS::M5aMkO #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Step1_v12::#NinjaNerd::04_Pharmacology::01_Basics::03_Antiplatelet,_Anticoagulant,_Thrombolytic_Agents #AK_Step1_v12::#AMBOSS::Xz09ri #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::03_Hypercoagulable_States #AK_Step1_v12::#NinjaNerd::06_Cardiovascular::04_Pharmacology::02_Warfarin_(MOA,_Indications,_AR,_CI) #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::17_Hypercoagulable_States #AK_Step1_v12::^Systems::HemeOnc::Hematology #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Other::Only_Step_1 #AK_Step1_v12::#UWorld::COMLEX::24199 #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::20_Hereditary_thrombophilias::*Protein_C_S_Deficiency #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::07_Anticoagulant_Drugs #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::09_Vitamin_K_Dependent_Coagulation_Factors #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::05_Thrombophilias #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::01_Bleeding_&_Clotting_Disorders::03_Hypercoagulable_Disorders_DDx #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::15_Antiplatelets,_Anticoagulants,_and_Thrombolytics #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::03_Warfarin #AK_Step1_v12::#UWorld::Step::1088 #AK_Step1_v12::#Pathoma::04_Hemostasis::04_Thrombosis #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_Hematology #AK_Step1_v12::#AMBOSS::tQaXB4 #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::01_Bleeding_&_Clotting_Disorders::01_Bleeding_Disorders:_Coagulation_Factor_Disorders_DDx #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::03_Hypercoagulable_States::Extra #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::05_Anticoagulants